Dysplasia

Global Myelodysplastic Syndrome Treatment Market to Surpass US$ 4,994.7 million by 2027 - Coherent Market Insights

Retrieved on: 
Lundi, novembre 25, 2019
Biotechnology, Pharmaceutical, Health, RTT, Myelodysplastic syndrome, Medical specialties, Medicine, Dysplasia, Clinical medicine, Antineoplastic drugs

According to Coherent Market Insights, the global myelodysplastic syndrome treatment market was valued at US$ 2,324.8 million in 2018, and is expected to exhibit a CAGR of 8.9% during the forecast period (2019-2027).

Key Points: 
  • According to Coherent Market Insights, the global myelodysplastic syndrome treatment market was valued at US$ 2,324.8 million in 2018, and is expected to exhibit a CAGR of 8.9% during the forecast period (2019-2027).
  • Key Trends and Analysis of the Global Myelodysplastic Syndrome Treatment Market:
    Increasing research and development activities by key players for developing novel therapeutic agents for the treatment of MDS is expected to drive growth of the myelodysplastic syndrome treatment market over the forecast period.
  • Among regions, Asia Pacific is expected to witness significant growth in the myelodysplastic syndrome treatment market over the forecast period.
  • Global Myelodysplastic Syndrome Treatment Market, By Drug:

Onconova Announces Five Presentations on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2019 Annual Meeting & Exposition

Retrieved on: 
Jeudi, novembre 7, 2019
Medical specialties, RTT, Medicine, Clinical medicine, Myelodysplastic syndrome, Blood, Dysplasia, Chronic myelomonocytic leukemia, GATA2 deficiency

Onconova has conducted trials with two other research compounds and has a pre-clinical program with a CDK4/6 and Ark5 inhibitor, ON 123300.

Key Points: 
  • Onconova has conducted trials with two other research compounds and has a pre-clinical program with a CDK4/6 and Ark5 inhibitor, ON 123300.
  • Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells.
  • This leads to low numbers of one or more types of circulating blood cells, and to the need for blood transfusions.
  • In MDS, some of the cells in the bone marrow are abnormal (dysplastic) and may have genetic abnormalities associated with them.

Bronchopulmonary Dysplasia (BPD): Global Market Insights, Epidemiology and Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Lundi, octobre 21, 2019
Health, Pharmaceutical, Neonatology, Medical specialties, Bronchopulmonary dysplasia, BPD, Dysplasia, Medicine, Branches of biology

The Bronchopulmonary Dysplasia epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries.

Key Points: 
  • The Bronchopulmonary Dysplasia epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries.
  • Among 7MM, estimates show higher population of Bronchopulmonary Dysplasia (BPD) in the United States, reaching to 14,243 cases in 2028
    This segment of the Bronchopulmonary Dysplasia report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs.
  • As per estimates, the market size of Bronchopulmonary Dysplasia was found to be USD 307.69 million in 2017.
  • This market is further expected to grow during the forecasted period of 2019-2028, owing to the launch of upcoming therapies.

Onconova Therapeutics, Inc. to Provide Corporate Update and Second Quarter 2019 Financial Results

Retrieved on: 
Mercredi, août 7, 2019
Medical specialties, RTT, Branches of biology, Hematology, Dysplasia, Histopathology, Oncology, Anemias, Myelodysplastic syndrome, Chronic myelomonocytic leukemia

The Company will host a conference call on August 14, 2019, at 9 a.m. Eastern Time to discuss these results.

Key Points: 
  • The Company will host a conference call on August 14, 2019, at 9 a.m. Eastern Time to discuss these results.
  • This leads to low numbers of one or more types of circulating blood cells, and to the need for blood transfusions.
  • In MDS, some of the cells in the bone marrow are abnormal (dysplastic) and may have genetic abnormalities associated with them.
  • Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037.

US Cervical Dysplasia Market and Competitive Landscape, 2019 - ResearchAndMarkets.com

Retrieved on: 
Vendredi, juillet 5, 2019
Pharmaceutical, Health, Oncology, Infectious causes of cancer, Oncology, Histopathology, Medicine, Medical specialties, Dysplasia, Health, Cervical intraepithelial neoplasia, RTT

The "US Cervical Dysplasia Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Cervical Dysplasia Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering.
  • The latest research, US Cervical Dysplasia Market and Competitive Landscape Highlights - 2019, provides comprehensive insights into Cervical Dysplasia pipeline products, Cervical Dysplasia epidemiology, Cervical Dysplasia market valuations and forecast, Cervical Dysplasia drugs sales and competitive landscape in the US.
  • Cervical Dysplasia pipeline: Find out the products in clinical trials for the treatment of Cervical Dysplasia by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Cervical Dysplasia drugs: Identify key products marketed and prescribed for Cervical Dysplasia in the US, including trade name, molecule name, and company
    Cervical Dysplasia market valuations: Find out the market size for Cervical Dysplasia drugs in 2018 in the US.
  • Find out how the market advanced from 2014 and forecast to 2024
    Cervical Dysplasia drugs market share: Find out the market shares for key Cervical Dysplasia drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Cervical Dysplasia products

Stringent Regulations for the Approval of New Drugs to Hamper the Growth of the Global Skeletal Dysplasia Market- QYR Consulting

Retrieved on: 
Mardi, juin 25, 2019
Rare diseases, Skeletal disorders, Branches of biology, Medicine, Health, Dysplasia, Histopathology, Oncology, Osteochondrodysplasia

Among skeletal dysplasia treatments, medication is expected to show substantial growth in the global market because of high adoption of orphan drugs.

Key Points: 
  • Among skeletal dysplasia treatments, medication is expected to show substantial growth in the global market because of high adoption of orphan drugs.
  • High incidence of diseases related to skeletal dysplasia and rising number of premature births are expected to augment the demand in North America.
  • Europe could be another region showing strong growth in the global skeletal dysplasia market owing to growing awareness about the disorder and its treatment.
  • The global skeletal dysplasia market is carefully analyzed with the use of SWOT, PESTLE, and Porter's Five Forces analyses.

Stringent Regulations for the Approval of New Drugs to Hamper the Growth of the Global Skeletal Dysplasia Market- QYR Consulting

Retrieved on: 
Mardi, juin 25, 2019
Rare diseases, Skeletal disorders, Branches of biology, Medicine, Health, Dysplasia, Histopathology, Oncology, Osteochondrodysplasia

Among skeletal dysplasia treatments, medication is expected to show substantial growth in the global market because of high adoption of orphan drugs.

Key Points: 
  • Among skeletal dysplasia treatments, medication is expected to show substantial growth in the global market because of high adoption of orphan drugs.
  • High incidence of diseases related to skeletal dysplasia and rising number of premature births are expected to augment the demand in North America.
  • Europe could be another region showing strong growth in the global skeletal dysplasia market owing to growing awareness about the disorder and its treatment.
  • The global skeletal dysplasia market is carefully analyzed with the use of SWOT, PESTLE, and Porter's Five Forces analyses.

Cervical Dysplasia Clinical Trial Pipeline Highlights 2019 - Track Competition, Identify Partners, Formulate Business Development Strategies - ResearchAndMarkets.com

Retrieved on: 
Mercredi, juin 12, 2019
Women, Health, Clinical trials, Pharmaceutical, Consumer, Health, Medicine, Infectious causes of cancer, Drug discovery, Clinical research, Design of experiments, Cervical intraepithelial neoplasia, Clinical trial, Dysplasia, HspE7

The "Global Cervical Dysplasia Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cervical Dysplasia Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.
  • Cervical Dysplasia Pipeline Highlights - 2019 provides most up-to-date information on key pipeline products in the global Cervical Dysplasia market.
  • It covers emerging therapies for Cervical Dysplasia in active clinical development stages including early and late stage clinical trials.
  • The report provides Cervical Dysplasia pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Orion Biotechnology's Chief Medical Officer to Present at the American Society of Clinical Oncology (ASCO) Meeting in Chicago

Retrieved on: 
Jeudi, mai 30, 2019
Cancer, Infectious causes of cancer, Papillomavirus, Gastrointestinal cancer, Anal cancer, RTT, Oncology, Intraepithelial neoplasia, Anal dysplasia, Human papillomavirus infection, Dysplasia, Anal Pap smear

His talk will be in the Gastrointestinal (Colorectal) cancer track and will focus on the surveillance and management of anal intraepithelial neoplasia in HIV and non-HIV infected patients.

Key Points: 
  • His talk will be in the Gastrointestinal (Colorectal) cancer track and will focus on the surveillance and management of anal intraepithelial neoplasia in HIV and non-HIV infected patients.
  • In the MTN-017 study which was conducted in the US, Peru, Thailand, and South Africa.
  • Dr. McGowan's laboratory showed that approximately 93% of MSM had evidence of anal HPV infection which is linked to the development of anal dysplasia and anal cancer (Cranston et al.
  • These patients should undergo regular surveillance to recognize and treat anal dysplasia to avoid progression to anal cancer," said Dr. McGowan.

Orion Biotechnology's Chief Medical Officer to Present at the American Society of Clinical Oncology (ASCO) Meeting in Chicago

Retrieved on: 
Jeudi, mai 30, 2019
Cancer, Infectious causes of cancer, Papillomavirus, Gastrointestinal cancer, Anal cancer, RTT, Oncology, Intraepithelial neoplasia, Anal dysplasia, Human papillomavirus infection, Dysplasia, Anal Pap smear

His talk will be in the Gastrointestinal (Colorectal) cancer track and will focus on the surveillance and management of anal intraepithelial neoplasia in HIV and non-HIV infected patients.

Key Points: 
  • His talk will be in the Gastrointestinal (Colorectal) cancer track and will focus on the surveillance and management of anal intraepithelial neoplasia in HIV and non-HIV infected patients.
  • In the MTN-017 study which was conducted in the US, Peru, Thailand, and South Africa.
  • Dr. McGowan's laboratory showed that approximately 93% of MSM had evidence of anal HPV infection which is linked to the development of anal dysplasia and anal cancer (Cranston et al.
  • These patients should undergo regular surveillance to recognize and treat anal dysplasia to avoid progression to anal cancer," said Dr. McGowan.